On Tuesday, Oracle Corporation (NYSE:ORCL)’s shares inclined 0.68% to $37.04. The market capitalization of Oracle Corporation (NYSE:ORCL) is $155.49 billion with the total traded volume of the company is 10.71 million. Turning to market valuation, the Price-to-Earnings ratio is 17.18, the Price-to-Sales ratio is 4.15 and the Price-to-Book ratio is finally 3.42. The dividend yield amounts to 1.62 percent and the beta ratio has a value of 1.22.
Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide.
Neurometrix Inc (NASDAQ:NURO)’s shares gained 0.43% to $2.31.
NeuroMetrix, Inc. (NURO) declared that it reached a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at a price of $1,000 per share, and two series of warrants to purchase an aggregate of about 10.8 million shares of common stock at an exercise price of $2.30 per share. The Company anticipates to receive gross proceeds from the offering of $13.8 million. It is predictable that about $6.3 million of the proceeds of the offering will be used to redeem 63,000 shares of Series B convertible preferred stock held by the healthcare dedicated institutional investor and the balance of the proceeds will be used for general working capital purposes.
The Series C convertible preferred stock is convertible at any time into an aggregate of about 5.4 million shares of common stock at an initial conversion price of $2.55 per share, subject to certain ownership limitations. The Series C convertible preferred stock is only entitled to dividends in the event dividends are paid on the Company’s common stock and will not have any preferences over the Company’s common stock, counting liquidation rights. The warrants are right away exercisable and 5.4 million of the warrants will expire twelve months from the effective date of a resale registration statement to be filed by the Company, and 5.4 million of the warrants will expire five years from the effective date of a resale registration statement to be filed by the Company.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as the exclusive placement agent for the transaction.
The offering is predictable to close on or about December 31, 2015, subject to satisfaction of customary closing conditions.
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis, and diabetes.
Michael Kors Holdings Ltd (NYSE:KORS)‘s shares surged 0.98% to $41.03. Michael Kors Holdings Ltd (NYSE:KORS) is now worth about $7.52 billion. The share price has made a 3.35% gain in the past 5 days and has lost -45.37% since 2015 kicked off. Analysts are forecasting EPS growth of 4.26% for next fiscal year and 3.77% growth in the next 5 years. The stock trades with a beta of 1.13. The stock price is below by -14.32% as contrast to the average price over the last 200 days. The company has 59.80% gross margins.
Michael Kors Holdings Limited engages in the design, marketing, distribution, and retailing of branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing.
